Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:18:07.594Z.
Calculation as of: 2026-10-06T17:18:07.594Z.
Quote observation: 2026-10-06T17:14:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8188a044afb190b383642178377b3b21d317b4c37addc3eac3f31d1e137b7514
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$125.56M
EV/EBITDA Ratio
N/A
TTM Avg
3271.29x
3Y Avg
2827.81x
5Y Avg
2827.81x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seer, Inc. (SEER) | $121.23M | N/A | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | N/A | N/A | N/A | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $120.19M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.00M | N/A | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.56M | N/A | 3271.29x | 2827.81x | 2827.81x |
| Entera Bio Ltd. (ENTX)vs › | $125.94M | N/A | 3.93x | 3.93x | 3.93x |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.00M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $115.55M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
